[Sleeping sickness, a reemerging sickness].
Human African Trypanosomiasis (THA) has reappeared in most intertropical countries of Black Africa and an estimated 400,000 new cases are reported every year. Genetic tests which now make possible the differentiation of morphologically similar trypanosome subspecies showed that a large variety of game and domestic animals act as reservoir hosts of Trypanosoma brucei gambiense, thus making it even more difficult to fight the disease. The detection of cases and their treatment are absolutely necessary in preventing the spread of the disease. This can only be carried out with mobile medical teams which seek out patients. This detection currently calls on techniques which isolate trypanosomes and serological techniques. The collection of data with regards to different geographical positions, makes it possible to determine exactly which regions are affected, possibly affected or sound. Although the diagnosis of the hemo-lymphatic stage can be determined without any great problem nowadays, the point at which the trypanosome invades CNS tissues and the ways in which it occurs are as yet unknown, even though the role of nitric oxyde and cytokines is better understood. Antibodies, anti-neurofilaments and anti-galactocerebrosides when found in the cerebro-spinal fluid are characteristic of the nervous stage of the disease. This condition is really sleeping sickness, not only hypersomnia. The more seriously the patient is affected the shorter the sleep-wake cycles are during the nycthemeron. These early disorders can be quickly reversed thanks to therapy, which to day uses melarsoprol, an arsenical drug, which cannot be of great promise as it is very toxic. Current research into nitro-imidazole derivatives (particularly megazol) seems a promising therapy as they were effective in vitro and in vivo, in rodents and primates.
Dumas
M
M
l'Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Faculté de Médecine-2, rue du docteur Marcland-87042 Limoges.
D000349:Africa / Q000453:epidemiology; D000818:Animals; D021821:Communicable Diseases, Emerging / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D004197:Disease Reservoirs; D006801:Humans; D008403:Mass Screening / Q000379:methods; D008549:Melarsoprol / Q000627:therapeutic use; D011159:Population Surveillance; D016052:Protozoan Vaccines; D013830:Thiadiazoles / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000627:therapeutic use; D014353:Trypanosomiasis, African / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D014611:Vaccination / Q000379:methods
D016052:Protozoan Vaccines; D013830:Thiadiazoles; D014344:Trypanocidal Agents; C013378:megazol; D008549:Melarsoprol